Longhang T Nguyen, MD
Internal Medicine · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Offices
- 3
Offices
3 locations · One Medical Group Inc · 330 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office at (888) 663-6331 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A67978 · Current
Licensed to practise in California · since 1999 · expires 2027-04-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$18,457
Medicare paid this office $18,457 for 45 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 30 | $8,700 | $107 |
| Long return visit (40+ min) | 12 | $2,949 | $147 |
| Short return visit (20+ min) | 12 | $926 | $66 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $627 | $14 |
| Insertion of needle into vein for collection of blood sample | 18 | $199 | $9 |
Who their Medicare patients are
45 Original Medicare patients in 2024. Average age 71 · Women 58% · Health risk score 0.96. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 67% · Diabetes 36% · Depression 24%.
The office billed $124,866, Medicare allowed $24,916 and paid $18,457; for 236 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 45 | 236 | 71 | 0.96 | $124,866 | $18,457 |
| 2023 | 36 | 161 | 70 | 0.77 | $96,351 | $15,207 |
| 2022 | 42 | 148 | 71 | 0.86 | $93,000 | $16,509 |
| 2021 | 41 | 161 | 72 | 0.59 | $80,526 | $17,353 |
| 2020 | 35 | 111 | 67 | 0.67 | $51,140 | $9,592 |
| 2019 | 27 | 105 | 72 | 0.85 | $59,120 | $10,607 |
| 2018 | 29 | 99 | 72 | 0.74 | $49,120 | $8,216 |
| 2017 | 24 | 88 | 75 | 0.69 | $36,919 | $6,466 |
| 2016 | 20 | 64 | 71 | 0.54 | $30,244 | $5,249 |
| 2015 | 20 | 41 | 69 | 0.84 | $18,411 | $3,691 |
| 2014 | 16 | 21 | 68 | 0.86 | $7,539 | $1,590 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 27 | $7,125 | $117 |
| Long return visit (40+ min) | 11 | $3,358 | $168 |
| Short return visit (20+ min) | 12 | $1,652 | $79 |
| Insertion of needle into vein for collection of blood sample | 24 | $252 | $8 |
2022: 2 services
| Return visit (30+ min) | 34 | $6,184 | $100 |
| Short return visit (20+ min) | 17 | $1,876 | $82 |
2021: 3 services
| Long return visit (40+ min) | 15 | $7,080 | $169 |
| Return visit (30+ min) | 23 | $5,370 | $114 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $2,096 | $161 |
2020: 1 service
| Return visit (30+ min) | 22 | $4,341 | $89 |
2019: 2 services
| Long return visit (40+ min) | 13 | $5,468 | $127 |
| Return visit (30+ min) | 17 | $4,380 | $88 |
2018: 3 services
| Return visit (30+ min) | 19 | $3,464 | $82 |
| Long return visit (40+ min) | 11 | $2,670 | $127 |
| Short return visit (20+ min) | 12 | $1,136 | $57 |
2017: 2 services
| Return visit (30+ min) | 17 | $2,961 | $82 |
| Short return visit (20+ min) | 11 | $902 | $56 |
2015: 1 service
| Return visit (30+ min) | 12 | $894 | $69 |
Drugs they prescribed that Part D paid
$22,819
Pharmacies billed $22,819 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
287 generic and fewer than 11 brand-name prescriptions · $22,819 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 14 | $14,056 | $1,004 |
| Atorvastatin | 36 | $237 | $7 |
| Lisinopril | 20 | $157 | $8 |
| Amlodipine Besylate | 19 | $84 | $4 |
| Metformin | 13 | $83 | $6 |
See all 8 drugs
| Eliquis | 14 | $14,056 | $1,004 |
| Atorvastatin | 36 | $237 | $7 |
| Lisinopril | 20 | $157 | $8 |
| Amlodipine Besylate | 19 | $84 | $4 |
| Metformin | 13 | $83 | $6 |
| Alprazolam | 12 | $53 | $4 |
| Rosuvastatin | 14 | $34 | $2 |
| Hydrocortisone | 11 | $30 | $3 |
Year by year
| 2024 | 329 | 36 | None | None | $22,819 |
| 2023 | 350 | 33 | None | None | $40,382 |
| 2022 | 374 | 43 | 0% (0) | None | $33,295 |
| 2021 | 230 | 30 | None | 15% | $18,843 |
| 2020 | 218 | 37 | None | None | $13,376 |
| 2019 | 203 | 29 | None | 11% | $13,472 |
| 2018 | 216 | 27 | None | 16% | $12,830 |
| 2017 | 209 | 23 | 7% (14) | None | $8,456 |
| 2016 | 134 | 16 | 0% (0) | None | $6,268 |
| 2015 | 51 | 11 | 0% (0) | None | $4,163 |
| 2014 | 151 | 70 | None | None | $5,361 |
| 2013 | 3,801 | 306 | 5% (187) | 22% | $201,684 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Atorvastatin | 41 | $380 | $9 |
| Levothyroxine | 12 | $210 | $18 |
| Losartan | 21 | $186 | $9 |
| Amlodipine Besylate | 16 | $139 | $9 |
| Metformin | 18 | $136 | $8 |
| Lisinopril | 12 | $107 | $9 |
2022: 7 drugs
| Levothyroxine | 14 | $255 | $18 |
| Atorvastatin | 35 | $207 | $6 |
| Losartan | 16 | $164 | $10 |
| Metformin | 20 | $145 | $7 |
| Amlodipine Besylate | 19 | $107 | $6 |
| Hydrocortisone | 12 | $69 | $6 |
| Trazodone | 15 | $54 | $4 |
2021: 4 drugs
| Levothyroxine | 11 | $224 | $20 |
| Atorvastatin | 18 | $190 | $11 |
| Amlodipine Besylate | 16 | $130 | $8 |
| Metformin | 14 | $90 | $6 |
2020: 5 drugs
| Losartan | 12 | $200 | $17 |
| Atorvastatin | 15 | $182 | $12 |
| Alprazolam | 15 | $149 | $10 |
| Amlodipine Besylate | 17 | $124 | $7 |
| Metformin | 12 | $102 | $9 |
2019: 3 drugs
| Losartan | 12 | $236 | $20 |
| Atorvastatin | 15 | $234 | $16 |
| Amlodipine Besylate | 27 | $194 | $7 |
2018: 4 drugs
| Atorvastatin | 16 | $256 | $16 |
| Levothyroxine | 15 | $185 | $12 |
| Amlodipine Besylate | 27 | $154 | $6 |
| Metformin | 11 | $94 | $9 |
2017: 3 drugs
| Valacyclovir | 11 | $174 | $16 |
| Amlodipine Besylate | 25 | $139 | $6 |
| Furosemide | 11 | $38 | $3 |
2016: 1 drug
| Amlodipine Besylate | 14 | $83 | $6 |
2013: 68 drugs
| Diovan | 56 | $16,194 | $289 |
| Lantus | 34 | $11,673 | $343 |
| Nexium | 42 | $10,245 | $244 |
| Crestor | 23 | $8,284 | $360 |
| Lantus Solostar | 24 | $7,707 | $321 |
| Humalog | 18 | $7,545 | $419 |
| Novolog Flexpen | 14 | $5,819 | $416 |
| Colcrys | 30 | $5,117 | $171 |
| Lovaza | 37 | $4,766 | $129 |
| Atorvastatin | 120 | $4,519 | $38 |
| Clopidogrel | 33 | $3,929 | $119 |
| Lidoderm | 14 | $3,765 | $269 |
| Losartan | 123 | $3,422 | $28 |
| Advair Diskus | 12 | $3,251 | $271 |
| Spiriva | 12 | $3,244 | $270 |
| Novolin 70-30 | 15 | $2,931 | $195 |
| Flovent Hfa | 11 | $2,805 | $255 |
| Metformin | 150 | $2,636 | $18 |
| Acarbose | 29 | $2,579 | $89 |
| Gabapentin | 58 | $2,509 | $43 |
| Fluticasone Propionate | 93 | $2,493 | $27 |
| Avodart | 15 | $2,444 | $163 |
| Glyburide | 45 | $2,440 | $54 |
| Simvastatin | 178 | $2,132 | $12 |
| Proair Hfa | 42 | $2,083 | $50 |
| Fosinopril | 67 | $1,943 | $29 |
| Amlodipine Besylate | 210 | $1,908 | $9 |
| Atenolol | 281 | $1,848 | $7 |
| Omeprazole | 135 | $1,831 | $14 |
| Patanol | 16 | $1,804 | $113 |
| Hydrocodone-Acetaminophen | 145 | $1,368 | $9 |
| Alendronate | 81 | $1,265 | $16 |
| Clonidine | 68 | $1,146 | $17 |
| Triamcinolone Acetonide | 39 | $1,082 | $28 |
| Glipizide | 90 | $1,067 | $12 |
| Isosorbide Dinitrate | 11 | $988 | $90 |
| Levothyroxine | 80 | $925 | $12 |
| Tamsulosin | 41 | $902 | $22 |
| Bd Ultra-Fine Pen Needle | 21 | $857 | $41 |
| Benazepril | 49 | $652 | $13 |
| Insulin | 21 | $542 | $26 |
| Potassium Chloride | 11 | $501 | $46 |
| Metoprolol | 50 | $495 | $10 |
| Oxybutynin Chloride Er | 13 | $468 | $36 |
| Donepezil | 16 | $455 | $28 |
| Furosemide | 84 | $443 | $5 |
| Hydrocortisone | 12 | $439 | $37 |
| Pravastatin | 14 | $406 | $29 |
| Finasteride | 13 | $374 | $29 |
| Hydrochlorothiazide | 94 | $361 | $4 |
| Baclofen | 43 | $297 | $7 |
| Doxepin | 16 | $282 | $18 |
| Paroxetine | 22 | $279 | $13 |
| Carvedilol | 15 | $253 | $17 |
| Ibuprofen | 44 | $252 | $6 |
| Triamterene-Hydrochlorothiazid | 30 | $249 | $8 |
| Lisinopril | 18 | $240 | $13 |
| Tizanidine | 27 | $206 | $8 |
| Pantoprazole | 12 | $161 | $13 |
| Allopurinol | 22 | $157 | $7 |
| Ranitidine | 17 | $154 | $9 |
| Citalopram Hbr | 28 | $149 | $5 |
| Nitrostat | 11 | $147 | $13 |
| Zolpidem | 24 | $114 | $5 |
| Acetaminophen-Codeine | 13 | $90 | $7 |
| Proctozone-Hc | 11 | $77 | $7 |
| Naphazoline | 12 | $76 | $6 |
| Propranolol | 11 | $64 | $6 |
Professional record
- NPI
- 1194894550
- Licence
- CA A67978California A67978: Current · expires 2027-04-30
- Trained
- University of California, San Francisco School of Medicine, 1997
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A679780
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 1 Embarcadero Ctr Ste 1900, San Francisco, CA, 94111
- NPI first listed
- 2006-11-07
- NPI last updated
- 2025-03-17
- NPI record certified
- 2025-03-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1299 Oakmead Pkwy, Sunnyvale, CA, 94085